Biologics in the treatment of pustular psoriasis

References

• Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Auto Rev. 2014;13(4–5):490–495.
   PubMed Web of Science ®Google Scholar
• Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2019;21:227–236.
   Web of Science ®Google Scholar
• Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–684.
   PubMed Web of Science ®Google Scholar
• Borges-Costa J, Silva R, Goncalves L, et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271–276..
   PubMed Web of Science ®Google Scholar
• Kluger N, Bessis D, Guillot B, et al. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). J Am Acad Dermatol. 2011;64:1154–1158.
   PubMed Web of Science ®Google Scholar
• Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27:1067–1077.
   PubMed Web of Science ®Google Scholar
• Hoegler KM, John AM, Handler MZ, et al. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32:1645–1651.
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67:279–288.
   PubMed Web of Science ®Google Scholar
• Raposo I, Palmoplantar Psoriasis TT. Palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17:349–358.
   PubMed Web of Science ®Google Scholar
• Sanchez IM, Sorenson E, Levin E, et al. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther (Heidelb). 2017;7:425–446.
   PubMed Web of Science ®Google Scholar
• Engin B, Askin O, Tuzun Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19–27.
   PubMed Web of Science ®Google Scholar
• Morales-Munera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013;168:820–824.
   PubMed Web of Science ®Google Scholar
• Bertelsen T, Kragballe K, Johansen C, et al. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol. 2014;53:e464–466.
   PubMed Web of Science ®Google Scholar
• Ito T, Mori T, Fujiyama T, et al. Dramatic exacerbation of palmoplantar pustulosis following strongly positive nickel patch testing. Int J Dermatol. 2014;53:e327–329.
   PubMed Web of Science ®Google Scholar
• de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J DermatolTreat. 2011;22:102–105.
   Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77:88–97 e85.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. Br J Dermatol. 2015;172:1613–1620.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737–744.
   PubMed Web of Science ®Google Scholar
• Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19:363–375.
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021–1026.
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J. 2019;17:37.
   PubMed Web of Science ®Google Scholar
• Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135:1067–1070 e1069.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133:2514–2521.
   PubMed Web of Science ®Google Scholar
• Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol. 2013;133:2634–2637.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–1369.
   PubMed Web of Science ®Google Scholar
• Zhu T, Jin H, Shu D, et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur J Dermatol. 2018;28:217–224.
   PubMed Web of Science ®Google Scholar
• Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol. 2016;136:1811–1819.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94:790–797.
   PubMed Web of Science ®Google Scholar
• Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018;178:614–618.
   PubMed Web of Science ®Google Scholar
• Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL-36 activity promotes clonal CD4(+) T-cell responses with IL-17A production in generalized pustular psoriasis. J Invest Dermatol. 2018;138:1338–1347.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–120.
   PubMed Web of Science ®Google Scholar
• Catapano M, Vergnano M, Romano M, et al. IL-36 promotes systemic IFN-I responses in severe forms of psoriasis. J Invest Dermatol. 2020;140:816–826.
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50:1195–1211.
   PubMed Web of Science ®Google Scholar
• Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol. 2014;28(Suppl 5):13–16.
   PubMedGoogle Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–437.
   PubMed Web of Science ®Google Scholar
• Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl). 2019;9:65–72.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136:2251–2259.
   PubMed Web of Science ®Google Scholar
• Mossner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178:740–748.
   PubMed Web of Science ®Google Scholar
• Wang TS, Chiu HY, Hong JB, et al. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308:55–63.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br J Dermatol. 2015;173:239–241.
   PubMed Web of Science ®Google Scholar
• Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br J Dermatol. 2017;176:212–215.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43–54.
   PubMed Web of Science ®Google Scholar
• Viguier M, Guigue P, Pages C, et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Inter Med. 2010;153:66–67.
   PubMed Web of Science ®Google Scholar
• Huffmeier U, Watzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–204.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132:e1043–1047.
   PubMed Web of Science ®Google Scholar
• Tauber M, Viguier M, Alimova E, et al. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br J Dermatol. 2014;171:646–649.
   PubMed Web of Science ®Google Scholar
• Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol. 2012;148:297–299.
   PubMedGoogle Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–983.
   PubMed Web of Science ®Google Scholar
• Storan ER, O’Gorman SM, Markham T. Generalized pustular psoriasis treated with ustekinumab. Clin Exp Dermatol. 2016;41:689–690.
   PubMed Web of Science ®Google Scholar
• Dauden E, Santiago-et-Sanchez-Mateos D, Sotomayor-Lopez E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol. 2010;163:1346–1347.
   PubMed Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/Interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152:825–828.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Komine M, Karakawa M, et al. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44:202–204.
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47:33–40.
   PubMed Web of Science ®Google Scholar
• Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, et al. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology. 2010;221:321–323.
   PubMed Web of Science ®Google Scholar
• Au SC, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J DermatolTreat. 2013;24:179–187.
   Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28:1298–1305.
   PubMed Web of Science ®Google Scholar
• Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology. 2015;230:97–100.
   PubMed Web of Science ®Google Scholar
• Adisen E, Ozer I, Temel B, et al. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents. Dermatol Ther. 2017;30:e12460.
   Web of Science ®Google Scholar
• Palacios-Alvarez I, Simal-Gomez G, Mas-Vidal A, et al. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti-TNF agents. J Dtsch Dermatol Ges. 2018;16:611–613.
   PubMed Web of Science ®Google Scholar
• Cymerman RM, Cohen DE. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy. JAMA Dermatol. 2016;152:346–348.
   PubMed Web of Science ®Google Scholar
• Adas A, Dadban A, Arnault JP, et al. Acrodermatitis continua of Hallopeau response to optimized biological therapy. Dermatol Online J. 2019;25:13030.
   PubMedGoogle Scholar
• Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017.
   PubMed Web of Science ®Google Scholar
• Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. J Dermatol. 2018;45:1353–1356.
   PubMed Web of Science ®Google Scholar
• Kostner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology (Oxford). 2018;57:936–938.
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Ucmak D, Hitraya-Low M, et al. Response to interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017;153:106–108.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80:1344–1352.
   PubMed Web of Science ®Google Scholar
• Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3:215–218.
   PubMedGoogle Scholar
• Smirnova LM, Vertieva EY, Olisova OY, et al. Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau. Biologics. 2019;13:83–87.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Teoli M, et al. Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019;32:e12899.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Japanese brodalumab study G. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–751.
   PubMed Web of Science ®Google Scholar
• Pinter A, Wilsmann-Theis D, Peitsch WK, et al. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol. 2019;46:426–430.
   PubMed Web of Science ®Google Scholar
• Milani-Nejad N, Kaffenberger J. Treatment of recalcitrant acrodermatitis continua of Hallopeau with brodalumab. J Drugs Dermatol. 2019;18:1047.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–362.
   PubMed Web of Science ®Google Scholar
• Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J DermatolTreat. 2019;1–3.
   Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45:850–854.
   PubMed Web of Science ®Google Scholar
• Malaviya R, Laskin JD, Laskin DL. Anti-TNFalpha therapy in inflammatory lung diseases. Pharmacol Ther. 2017;180:90–98.
   PubMed Web of Science ®Google Scholar
• Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213–216.
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, Casciello C, et al. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008;216:355–360.
   PubMed Web of Science ®Google Scholar
• Lo Schiavo A, Brancaccio G, Puca RV, et al. Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol. 2012;24:233–234.
   PubMed Web of Science ®Google Scholar
• Fialova J, Vojackova N, Vanousova D, et al. Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther. 2014;27:105–108.
   PubMed Web of Science ®Google Scholar
• Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep. 2018;4:192–195.
   PubMedGoogle Scholar
• Ricotti C, Kerdel FA. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol. 2007;6:738–740.
   PubMedGoogle Scholar
• Rodriguez-Lomba E, Baniandres O, Cano N, et al. Generalised pustular psoriasis and neutrophilic cholangitis: an infrequently reported association with excellent response to tumour necrosis factor inhibitors. Australas J Dermatol. 2017;58:70–71.
   PubMed Web of Science ®Google Scholar
• Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213:350–352.
   PubMed Web of Science ®Google Scholar
• Mazzotta A, Saraceno R, Esposito M, et al. Etanercept, childhood and long-term safety: a case of five years treatment. Eur J Dermatol. 2011;21:776–777.
   PubMed Web of Science ®Google Scholar
• Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol. 2009;161:964–966.
   PubMed Web of Science ®Google Scholar
• Viguier M, Aubin F, Delaporte E, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148:1423–1425.
   PubMedGoogle Scholar
• Puig L, Barco D, Vilarrasa E, et al. Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review. Dermatology. 2010;220:154–158.
   PubMed Web of Science ®Google Scholar
• Thielen AM, Barde C, Marazza G, et al. Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade). Dermatology. 2008;217:137–139.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Diepgen TL. Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau. J Dtsch Dermatol Ges. 2007;5:489–492.
   PubMedGoogle Scholar
• Kazinski K, Joyce KM, Hodson D. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau. J Drugs Dermatol. 2005;4:360–364.
   PubMedGoogle Scholar
• Bonish B, Rashid RM, Swan J. Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? J Drugs Dermatol. 2006;5:903–904.
   PubMedGoogle Scholar
• Silpa-archa N, Wongpraparut C. A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept. J Med Assoc Thai. 2011;94:1154–1157.
   PubMedGoogle Scholar
• Adisen E, Oztas M, Gurer MA. Lack of efficacy of etanercept in acrodermatitis continua of Hallopeau. Int J Dermatol. 2007;46:1205–1207.
   PubMed Web of Science ®Google Scholar
• Routhouska SB, Sheth PB, Korman NJ. Long-term management of generalized pustular psoriasis with infliximab: case series. J Cutan Med Surg. 2008;12:184–188.
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329–336.
   PubMed Web of Science ®Google Scholar
• Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43:1439–1440.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Endo K, Akasaka T, et al. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol. 2015;29:2054–2056.
   PubMed Web of Science ®Google Scholar
• Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg. 2004;8:224–228.
   PubMed Web of Science ®Google Scholar
• Tang MM, Spanou Z, Tang H, et al. Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin. Dermatology. 2012;225:338–343.
   PubMed Web of Science ®Google Scholar
• Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. Ann Dermatol. 2014;26:787–788.
   PubMed Web of Science ®Google Scholar
• Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J Am Acad Dermatol. 2013;68:e187–189.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Matsumoto Y, Abe N, et al. Perioperative management of tumor necrosis factor-alpha blocker-treated psoriatic patients: case reports and review. J Dermatol. 2016;43:190–193.
   PubMed Web of Science ®Google Scholar
• Vieira Serrao V, Martins A, Lopes MJ. Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol. 2008;18:71–73.
   PubMed Web of Science ®Google Scholar
• Chandran NS, Chong WS. A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis. Australas J Dermatol. 2010;51:29–31.
   PubMed Web of Science ®Google Scholar
• Weishaupt C, Metze D, Luger TA, et al. Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges. 2007;5:397–399.
   PubMedGoogle Scholar
• Sheth N, Greenblatt DT, Acland K, et al. Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol. 2009;34:521–522.
   PubMed Web of Science ®Google Scholar
• Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol. 2004;150:367.
   PubMed Web of Science ®Google Scholar
• Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology. 2010;220:71–76.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Maeda T, Abe N, et al. Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol. 2015;42:94–95.
   PubMed Web of Science ®Google Scholar
• Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29:164–167.
   PubMed Web of Science ®Google Scholar
• Chen W, Peng C, Ding Y, et al. Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report. Dermatol Ther. 2019;32:e12838.
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Weger W, Salmhofer W, et al. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32:e13–14.
   PubMed Web of Science ®Google Scholar
• Tsang V, Dvorakova V, Enright F, et al. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e117–e119.
   PubMed Web of Science ®Google Scholar
• Furusawa K, Hasegawa T, Ikeda S. Immunosuppressant and infliximab-resistant generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis. Ther Apher Dial. 2012;16:379–380.
   PubMed Web of Science ®Google Scholar
• Mang R, Ruzicka T, Stege H. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade). Br J Dermatol. 2004;150:379–380.
   PubMed Web of Science ®Google Scholar
• Rubio C, Martin MA, Arranz Sanchez DM, et al. Excellent and prolonged response to infliximab in a case of recalcitrant acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2009;23:707–708.
   PubMed Web of Science ®Google Scholar
• Ahmad K, Rogers S. Three years’ experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol. 2006;31:630–633.
   PubMed Web of Science ®Google Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371–1380.
   PubMed Web of Science ®Google Scholar
• Gallo E, Llamas-Velasco M, Dauden E, et al. Refractory generalized pustular psoriasis responsive to a combination of adalimumab and acitretin. Int J Dermatol. 2013;52:1610–1611.
   PubMed Web of Science ®Google Scholar
• Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J DermatolTreat. 2005;16:350–352.
   Google Scholar
• Zangrilli A, Papoutsaki M, Talamonti M, et al. Long-term efficacy of adalimumab in generalized pustular psoriasis. J DermatolTreat. 2008;19:185–187.
   Google Scholar
• Kimura U, Kinoshita A, Sekigawa I, et al. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis. J Dermatol. 2012;39:1071–1072.
   PubMed Web of Science ®Google Scholar
• Jordan J, Bieber T, Wilsmann-Theis D. Adalimumab: safe and successful in severe pustular psoriasis. J Eur Acad Dermatol Venereol. 2009;23:592–593.
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Arenberger P, Gkalpakioti P, et al. A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab. J Eur Acad Dermatol Venereol. 2015;29:2063–2064.
   PubMed Web of Science ®Google Scholar
• Hansel K, Marietti R, Tramontana M, et al. Childhood generalized pustular psoriasis: successful long-term treatment with adalimumab. Dermatol Ther. 2020;33:e13294.
   PubMed Web of Science ®Google Scholar
• Di Costanzo L, Napolitano M, Patruno C, et al. Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab. J DermatolTreat. 2014;25:489–494.
   Google Scholar
• Crowley EL, Maliyar K, Rodriguez-Bolanos F, et al. Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19829620.
   PubMed Web of Science ®Google Scholar
• Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol. 2013;93:588–589.
   PubMed Web of Science ®Google Scholar
• Sopkovich JA, Anetakis Poulos G, Wong HK. Acrodermatitis continua of hallopeau successfully treated with adalimumab. J Clin Aesthet Dermatol. 2012;5:60–62.
   PubMedGoogle Scholar
• Ryan C, Collins P, Kirby B, et al. Treatment of acrodermatitis continua of Hallopeau with adalimumab. Br J Dermatol. 2009;160:203–205.
   PubMed Web of Science ®Google Scholar
• Hansel K, Bianchi L, Lanza F, et al. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venereol. 2017;97:346–350.
   PubMed Web of Science ®Google Scholar
• Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol. 2000;143:1121–1122.
   PubMed Web of Science ®Google Scholar
• Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor-alpha inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol. 2014;171:1546–1549.
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529–539.
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154:309–316.
   PubMed Web of Science ®Google Scholar
• McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79:893–900.
   PubMed Web of Science ®Google Scholar